Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$24.33

-0.05 (-0.21%)

04:55
11/28/18
11/28
04:55
11/28/18
04:55

Mallinckrodt management to meet with Leerink

Meetings to be held in Philadelphia on November 27 and in the Mid-Atlantic area on November 28 hosted by Leerink.

  • 28

    Nov

  • 02

    Dec

MNK Mallinckrodt
$24.33

-0.05 (-0.21%)

11/19/18
WELS
11/19/18
NO CHANGE
Target $27
WELS
Market Perform
OIG response to Mallinckrodt's Acthar proposal a negative, says Wells Fargo
The Office of the Inspector General of the Department of Health and Human Services has advised Mallinckrodt (MNK) that the proposed patient access program for Acthar in hospitals would "present more than a minimal risk of fraud and abuse under the anti-kickback statute," Wells Fargo analyst David Maris tells investors in a research note. While not a setback to current Acthar sales, this is a negative outcome in Mallinckrodt's efforts to expand access to the drug, says the analyst. He believes the OIG opinion effectively states that if Mallinckrodt gives Acthar to hospitals for free for a chronic syndrome, and then will provide it for free only to those patients when discharged whose insurance won't pay for it, then the company is effectively giving away a product to help get those with commercial insurance to pay for it when out of the hospital. Maris thinks Mallinckrodt's Acthar faces a "challenging environment" with HHS and OIG. He keeps a Market Perform rating on the shares with a $27 price target.
11/23/18
ADAM
11/23/18
NO CHANGE
Target $40
ADAM
Buy
Mallinckrodt Acthar franchise not impacted by HHS opinion, says Canaccord
Canaccord analyst Dewey Steadman noted Mallinckrodt received an advisory opinion from the HHS denying what appeared to be the company's request to distribute free vials of Acthar to hospitals to encourage use in West syndrome and infantile spasms. The analyst views the opinion as clearly anti-patient and not particularly negative to the IS sub-franchise within Acthar, as the current distribution status quo appears to have been maintained. He sees the weakness in the shares as a chance to build a position in the name. Steadman reiterated his Buy rating and $40 price target on Mallinckrodt shares.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $35
JEFF
Buy
Atlantis study unlikely to impact Mallinckrodt script trends, says Jefferies
Mallinckrodt shares sold off 8% yesterday on a delayed circulation of results from the Atlantis trial, a randomized prospective study aimed at examining safety and efficacy of Acthar in treating pediatric patients with nephrotic syndrome, Jefferies analyst Anthony Petrone tells investors in a research note. The trial was stopped at interim as the majority of participants treated with Acthar experienced a relapse within 23 days, which was similar to the control arm, says the analyst. Hence, Acthar showed no benefit at preventing relapse of nephrotic syndrome in pediatric patients, Petrone notes. The analyst says he confirmed that the Atlantis study was an investigator-led study and was not officially sponsored by the company. He adds that Acthar use in pediatric nephrotic syndrome is minimal and that several other NS study readouts "point toward efficacy in refractive patients." As such, Petrone does not see the Atlantis results as being pivotal in impacting near-term prescription trends or as an indicator of future readouts to come in 2019. He keeps a Buy rating on Mallinckrodt with a $35 price target.
11/27/18
ADAM
11/27/18
NO CHANGE
Target $40
ADAM
Buy
Citron tweet on Mallinckrodt an 'Acthar nothingburger,' says Canaccord
Canaccaord analyst Dewey Steadman tells investors in a research note that yesterday's tweet by Citron Research with a link to an article in Clinical Journal of the American Society of Nephrology that showed Mallinckrodt's Acthar showed little efficacy in pediatric nephrotic syndrome patients is "essentially old news" that is not relevant to the current Acthar franchise. The analyst, who called the news "an Acthar nothingburger," sees robust data in six indications as key drivers to tamp down over-reactions to non-important data reads. The analyst reiterates a Buy rating on Mallinckrodt with a $40 price target and sees an "even better" entry point into the story at these levels.

TODAY'S FREE FLY STORIES

GIS

General Mills

$47.24

-0.365 (-0.77%)

20:25
03/19/19
03/19
20:25
03/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

TRN

Trinity Industries

$22.46

-0.25 (-1.10%)

20:20
03/19/19
03/19
20:20
03/19/19
20:20
Hot Stocks
Trinity Industries names Leldon Echols chairman of the board »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

TIGR

UP Fintech

$0.00

(0.00%)

20:06
03/19/19
03/19
20:06
03/19/19
20:06
Syndicate
UP Fintech 13M share IPO priced at $8.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

SND

Smart Sand

$4.27

-0.4 (-8.57%)

20:01
03/19/19
03/19
20:01
03/19/19
20:01
Initiation
Smart Sand initiated at B. Riley FBR »

Smart Sand initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$0.00

(0.00%)

20:00
03/19/19
03/19
20:00
03/19/19
20:00
Initiation
Lyft initiated at DA Davidson »

Lyft initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DERM

Dermira

$14.13

1.52 (12.05%)

19:40
03/19/19
03/19
19:40
03/19/19
19:40
Syndicate
Dermira 9.8M share Secondary priced at $13.25 per share »

Citi, Cowen, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:38
03/19/19
03/19
19:38
03/19/19
19:38
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

TORC

ResTORbio

$7.16

-1.81 (-20.18%)

19:34
03/19/19
03/19
19:34
03/19/19
19:34
Syndicate
ResTORbio 7.2M share Secondary priced at $6.95 »

BofA/Merrill, SVB Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:33
03/19/19
03/19
19:33
03/19/19
19:33
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

PFE

Pfizer

$42.32

0.51 (1.22%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

19:17
03/19/19
03/19
19:17
03/19/19
19:17
Hot Stocks
Pfizer, Merck KGaA discontinue Phase III JAVELIN Ovarian PARP study »

Merck KGaA (MKGAY) and…

PFE

Pfizer

$42.32

0.51 (1.22%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 30

    Apr

  • 18

    May

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:11
03/19/19
03/19
19:11
03/19/19
19:11
Hot Stocks
Google outlines changes to Android mobile options, ad formats in Europe »

Google said in a blog…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:08
03/19/19
03/19
19:08
03/19/19
19:08
Periodicals
Google offers Android, product ad concessions for Europe, WSJ says »

Google intends to ask all…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

SIEN

Sientra

$8.81

-0.4 (-4.34%)

18:51
03/19/19
03/19
18:51
03/19/19
18:51
Recommendations
Sientra analyst commentary at Wells Fargo »

Sientra implied costs to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:50
03/19/19
03/19
18:50
03/19/19
18:50
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:45
03/19/19
03/19
18:45
03/19/19
18:45
Hot Stocks
FedEx CEO: Domestic business is pretty good »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

LYFT

Lyft

$0.00

(0.00%)

18:41
03/19/19
03/19
18:41
03/19/19
18:41
Periodicals
Lyft IPO oversubscribed so far, Reuters reports »

Lyft's IPO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

NSTG

NanoString

$24.27

-3.03 (-11.10%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Syndicate
NanoString 4.5M share Secondary priced at $23.00 »

JPMorgan, UBS and Cowen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

GLD

SPDR Gold Shares

$123.39

0.35 (0.28%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Hot Stocks
Breaking Hot Stocks news story on SPDR Gold Shares »

SPDR Gold Shares holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.